WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure

Core Insights - WuXi Biologics has been recognized for its commitment to sustainability and transparency by receiving the Outstanding ESG Disclosure award at the Hong Kong ESG Reporting Awards (HERA) 2025, marking a significant achievement in its ESG journey [1][2] - The company emphasizes that transparent ESG reporting serves as a strategic advantage, enhancing trust and confidence among stakeholders, including clients, investors, and regulators [2][3] ESG Commitment - WuXi Biologics has a history of receiving accolades for its ESG efforts, including the ESG Report Benchmark Award from HERA in the previous year, which underscores the consistency of its progressive ESG initiatives [2] - The company actively participates in global sustainability initiatives, such as the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), and has received numerous recognitions, including an MSCI AAA Rating and a Platinum Medal from EcoVadis [4] Business Operations - As of June 30, 2025, WuXi Biologics supports 864 integrated client projects, with 24 of these in commercial manufacturing, showcasing its extensive operational capabilities [6] - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore, leveraging its expertise to provide efficient and cost-effective biologics solutions [6] Sustainability Focus - WuXi Biologics views sustainability as essential for long-term business growth and is committed to driving green technology innovations to offer advanced Green CRDMO solutions [7] - The company aims to create shared value by collaborating with stakeholders to foster positive social and environmental impacts, promoting responsible practices throughout the value chain [7]